| Reagan-Udall Foundation

Zeroing in on what is needed to improve operations, including the PMTA process, Booth said a review of the Reagan-Udall Foundation report is critical.

Coverage

Read more about CSP Daily News: After Mass Layoffs at the FDA's Center for Tobacco Products, What Happens Next?

In addition to the new AACR award, Dr. Pazdur has received numerous awards and honors throughout his career: the Regulatory Affairs Professionals Society Patient-Centered Health Award (2021), the University of Chicago Cancer Research Foundation Simon M. Shubitz Cancer Prize and Lectureship (2020), the FDA Alumni Association Harvey W. Wiley Award (2019), recognition as one of OncLive’s Giants of Cancer Care (2019), the Reagan-Udall Foundation Innovations in Regulatory Science Award for Leadership (2018)...

Coverage

Read more about The ASCO Post: Richard Pazdur, MD, Honored With 2025 AACR Enduring Impact Award for Transformative Service to Cancer Science and Medicine

Read more about Daiichi Sankyo

Expanded Access Listings

Medical Access Program for Patritumab Deruxtecan

Conditions

Epidermal Growth Factor Receptor (EGFR)-Mutated Non Small Cell Lung Cancer

The purpose of this Medical Access Program is to provide access to HER3-DXd for eligiblepatients with NSCLC who, in their treating physician's opinion, have an unmet clinicalneed which cannot be treated with approved and commercially available drugs and whocannot enter a clinical trial prior to commercial availability.